nodes	percent_of_prediction	percent_of_DWPC	metapath
Etravirine—CYP2C9—Fluorouracil—head and neck cancer	0.142	0.276	CbGbCtD
Etravirine—ABCB1—Vinblastine—head and neck cancer	0.127	0.248	CbGbCtD
Etravirine—ABCB1—Docetaxel—head and neck cancer	0.105	0.205	CbGbCtD
Etravirine—CYP3A4—Vinblastine—head and neck cancer	0.0763	0.149	CbGbCtD
Etravirine—CYP3A4—Docetaxel—head and neck cancer	0.0629	0.123	CbGbCtD
Etravirine—ABCB4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.0109	0.146	CbGpPWpGaD
Etravirine—Blister—Hydroxyurea—head and neck cancer	0.0101	0.0246	CcSEcCtD
Etravirine—Prurigo—Docetaxel—head and neck cancer	0.00822	0.0199	CcSEcCtD
Etravirine—Blister—Fluorouracil—head and neck cancer	0.00729	0.0177	CcSEcCtD
Etravirine—Disorientation—Hydroxyurea—head and neck cancer	0.00593	0.0144	CcSEcCtD
Etravirine—Hepatic failure—Hydroxyurea—head and neck cancer	0.0059	0.0143	CcSEcCtD
Etravirine—Renal failure acute—Hydroxyurea—head and neck cancer	0.00574	0.0139	CcSEcCtD
Etravirine—Dermatitis bullous—Hydroxyurea—head and neck cancer	0.00555	0.0135	CcSEcCtD
Etravirine—Haemoglobin decreased—Docetaxel—head and neck cancer	0.00551	0.0134	CcSEcCtD
Etravirine—Inflammation—Fluorouracil—head and neck cancer	0.00542	0.0132	CcSEcCtD
Etravirine—Angina pectoris—Vinblastine—head and neck cancer	0.00489	0.0119	CcSEcCtD
Etravirine—Breast disorder—Hydroxyurea—head and neck cancer	0.00479	0.0116	CcSEcCtD
Etravirine—Pancreatitis—Hydroxyurea—head and neck cancer	0.00449	0.0109	CcSEcCtD
Etravirine—Acute coronary syndrome—Vinblastine—head and neck cancer	0.00442	0.0107	CcSEcCtD
Etravirine—Neuropathy peripheral—Vinblastine—head and neck cancer	0.00439	0.0107	CcSEcCtD
Etravirine—Myocardial infarction—Vinblastine—head and neck cancer	0.00439	0.0107	CcSEcCtD
Etravirine—Disorientation—Fluorouracil—head and neck cancer	0.00427	0.0104	CcSEcCtD
Etravirine—Amnesia—Fluorouracil—head and neck cancer	0.00406	0.00986	CcSEcCtD
Etravirine—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.00401	0.00972	CcSEcCtD
Etravirine—Hypoaesthesia—Vinblastine—head and neck cancer	0.004	0.00971	CcSEcCtD
Etravirine—Dermatitis bullous—Fluorouracil—head and neck cancer	0.00399	0.00969	CcSEcCtD
Etravirine—Stomatitis—Hydroxyurea—head and neck cancer	0.00398	0.00967	CcSEcCtD
Etravirine—Inflammation—Docetaxel—head and neck cancer	0.00391	0.00949	CcSEcCtD
Etravirine—ABCB4—PPARA activates gene expression—YAP1—head and neck cancer	0.00389	0.052	CbGpPWpGaD
Etravirine—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00386	0.00938	CcSEcCtD
Etravirine—ABCB4—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—YAP1—head and neck cancer	0.00381	0.0509	CbGpPWpGaD
Etravirine—Dry skin—Fluorouracil—head and neck cancer	0.0035	0.00849	CcSEcCtD
Etravirine—Angiopathy—Hydroxyurea—head and neck cancer	0.00333	0.00808	CcSEcCtD
Etravirine—Eosinophilia—Fluorouracil—head and neck cancer	0.00327	0.00793	CcSEcCtD
Etravirine—Ill-defined disorder—Vinblastine—head and neck cancer	0.00325	0.00788	CcSEcCtD
Etravirine—Anaemia—Vinblastine—head and neck cancer	0.00324	0.00785	CcSEcCtD
Etravirine—Angina pectoris—Fluorouracil—head and neck cancer	0.00321	0.0078	CcSEcCtD
Etravirine—Malaise—Vinblastine—head and neck cancer	0.00316	0.00766	CcSEcCtD
Etravirine—Vertigo—Vinblastine—head and neck cancer	0.00315	0.00763	CcSEcCtD
Etravirine—Hepatic failure—Docetaxel—head and neck cancer	0.00307	0.00744	CcSEcCtD
Etravirine—Convulsion—Vinblastine—head and neck cancer	0.00303	0.00736	CcSEcCtD
Etravirine—Hypertension—Vinblastine—head and neck cancer	0.00302	0.00734	CcSEcCtD
Etravirine—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00296	0.00719	CcSEcCtD
Etravirine—Anaemia—Hydroxyurea—head and neck cancer	0.00295	0.00716	CcSEcCtD
Etravirine—Discomfort—Vinblastine—head and neck cancer	0.00295	0.00715	CcSEcCtD
Etravirine—Atrial fibrillation—Docetaxel—head and neck cancer	0.00291	0.00705	CcSEcCtD
Etravirine—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.0029	0.00704	CcSEcCtD
Etravirine—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.00288	0.007	CcSEcCtD
Etravirine—Myocardial infarction—Fluorouracil—head and neck cancer	0.00288	0.007	CcSEcCtD
Etravirine—Dermatitis bullous—Docetaxel—head and neck cancer	0.00288	0.00699	CcSEcCtD
Etravirine—Malaise—Hydroxyurea—head and neck cancer	0.00288	0.00699	CcSEcCtD
Etravirine—Stomatitis—Fluorouracil—head and neck cancer	0.00287	0.00696	CcSEcCtD
Etravirine—Conjunctivitis—Fluorouracil—head and neck cancer	0.00286	0.00694	CcSEcCtD
Etravirine—Thrombocytopenia—Vinblastine—head and neck cancer	0.0028	0.00679	CcSEcCtD
Etravirine—Convulsion—Hydroxyurea—head and neck cancer	0.00277	0.00671	CcSEcCtD
Etravirine—Anorexia—Vinblastine—head and neck cancer	0.00272	0.00661	CcSEcCtD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.0027	0.00655	CcSEcCtD
Etravirine—Discomfort—Hydroxyurea—head and neck cancer	0.00269	0.00652	CcSEcCtD
Etravirine—Hypoaesthesia—Fluorouracil—head and neck cancer	0.00263	0.00637	CcSEcCtD
Etravirine—ABCB4—Fatty acid, triacylglycerol, and ketone body metabolism—YAP1—head and neck cancer	0.00263	0.035	CbGpPWpGaD
Etravirine—Infection—Hydroxyurea—head and neck cancer	0.00259	0.00628	CcSEcCtD
Etravirine—Paraesthesia—Vinblastine—head and neck cancer	0.00257	0.00623	CcSEcCtD
Etravirine—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00256	0.0062	CcSEcCtD
Etravirine—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00255	0.00619	CcSEcCtD
Etravirine—Skin disorder—Hydroxyurea—head and neck cancer	0.00253	0.00614	CcSEcCtD
Etravirine—Dry skin—Docetaxel—head and neck cancer	0.00252	0.00613	CcSEcCtD
Etravirine—Breast disorder—Docetaxel—head and neck cancer	0.00249	0.00604	CcSEcCtD
Etravirine—Anorexia—Hydroxyurea—head and neck cancer	0.00248	0.00603	CcSEcCtD
Etravirine—Decreased appetite—Vinblastine—head and neck cancer	0.00248	0.00603	CcSEcCtD
Etravirine—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.00248	0.00602	CcSEcCtD
Etravirine—Pain—Vinblastine—head and neck cancer	0.00244	0.00593	CcSEcCtD
Etravirine—Constipation—Vinblastine—head and neck cancer	0.00244	0.00593	CcSEcCtD
Etravirine—Feeling abnormal—Vinblastine—head and neck cancer	0.00235	0.00571	CcSEcCtD
Etravirine—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.00235	0.0314	CbGpPWpGaD
Etravirine—Bronchospasm—Docetaxel—head and neck cancer	0.00234	0.00568	CcSEcCtD
Etravirine—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00234	0.00567	CcSEcCtD
Etravirine—Angina pectoris—Docetaxel—head and neck cancer	0.00232	0.00563	CcSEcCtD
Etravirine—Somnolence—Hydroxyurea—head and neck cancer	0.00232	0.00562	CcSEcCtD
Etravirine—Decreased appetite—Hydroxyurea—head and neck cancer	0.00227	0.0055	CcSEcCtD
Etravirine—Abdominal pain—Vinblastine—head and neck cancer	0.00226	0.00548	CcSEcCtD
Etravirine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00225	0.00546	CcSEcCtD
Etravirine—Fatigue—Hydroxyurea—head and neck cancer	0.00225	0.00545	CcSEcCtD
Etravirine—Constipation—Hydroxyurea—head and neck cancer	0.00223	0.00541	CcSEcCtD
Etravirine—Pain—Hydroxyurea—head and neck cancer	0.00223	0.00541	CcSEcCtD
Etravirine—ABCB4—PPARA activates gene expression—CYP1A1—head and neck cancer	0.00219	0.0292	CbGpPWpGaD
Etravirine—Vision blurred—Fluorouracil—head and neck cancer	0.00217	0.00526	CcSEcCtD
Etravirine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00215	0.00521	CcSEcCtD
Etravirine—ABCB4—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CYP1A1—head and neck cancer	0.00214	0.0286	CbGpPWpGaD
Etravirine—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.00214	0.0286	CbGpPWpGaD
Etravirine—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.00214	0.0286	CbGpPWpGaD
Etravirine—Anaemia—Fluorouracil—head and neck cancer	0.00212	0.00516	CcSEcCtD
Etravirine—Hypersensitivity—Vinblastine—head and neck cancer	0.00211	0.00511	CcSEcCtD
Etravirine—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.0021	0.00511	CcSEcCtD
Etravirine—Acute coronary syndrome—Docetaxel—head and neck cancer	0.00209	0.00508	CcSEcCtD
Etravirine—Renal failure—Docetaxel—head and neck cancer	0.00209	0.00506	CcSEcCtD
Etravirine—Neuropathy peripheral—Docetaxel—head and neck cancer	0.00208	0.00505	CcSEcCtD
Etravirine—Myocardial infarction—Docetaxel—head and neck cancer	0.00208	0.00505	CcSEcCtD
Etravirine—Stomatitis—Docetaxel—head and neck cancer	0.00207	0.00502	CcSEcCtD
Etravirine—Conjunctivitis—Docetaxel—head and neck cancer	0.00206	0.00501	CcSEcCtD
Etravirine—Body temperature increased—Hydroxyurea—head and neck cancer	0.00206	0.005	CcSEcCtD
Etravirine—Asthenia—Vinblastine—head and neck cancer	0.00205	0.00498	CcSEcCtD
Etravirine—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00201	0.00487	CcSEcCtD
Etravirine—Convulsion—Fluorouracil—head and neck cancer	0.00199	0.00483	CcSEcCtD
Etravirine—Diarrhoea—Vinblastine—head and neck cancer	0.00196	0.00474	CcSEcCtD
Etravirine—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.00195	0.026	CbGpPWpGaD
Etravirine—Discomfort—Fluorouracil—head and neck cancer	0.00193	0.00469	CcSEcCtD
Etravirine—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00192	0.00466	CcSEcCtD
Etravirine—Hepatitis—Docetaxel—head and neck cancer	0.00191	0.00462	CcSEcCtD
Etravirine—Hypoaesthesia—Docetaxel—head and neck cancer	0.0019	0.0046	CcSEcCtD
Etravirine—Confusional state—Fluorouracil—head and neck cancer	0.00189	0.00459	CcSEcCtD
Etravirine—Dizziness—Vinblastine—head and neck cancer	0.00189	0.00459	CcSEcCtD
Etravirine—Urinary tract disorder—Docetaxel—head and neck cancer	0.00188	0.00457	CcSEcCtD
Etravirine—Connective tissue disorder—Docetaxel—head and neck cancer	0.00187	0.00454	CcSEcCtD
Etravirine—Asthenia—Hydroxyurea—head and neck cancer	0.00187	0.00454	CcSEcCtD
Etravirine—Urethral disorder—Docetaxel—head and neck cancer	0.00187	0.00453	CcSEcCtD
Etravirine—Infection—Fluorouracil—head and neck cancer	0.00186	0.00452	CcSEcCtD
Etravirine—Nervous system disorder—Fluorouracil—head and neck cancer	0.00184	0.00446	CcSEcCtD
Etravirine—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00184	0.00446	CcSEcCtD
Etravirine—Vomiting—Vinblastine—head and neck cancer	0.00182	0.00441	CcSEcCtD
Etravirine—Erythema multiforme—Docetaxel—head and neck cancer	0.0018	0.00437	CcSEcCtD
Etravirine—Headache—Vinblastine—head and neck cancer	0.00179	0.00434	CcSEcCtD
Etravirine—Anorexia—Fluorouracil—head and neck cancer	0.00179	0.00434	CcSEcCtD
Etravirine—Diarrhoea—Hydroxyurea—head and neck cancer	0.00178	0.00433	CcSEcCtD
Etravirine—Eye disorder—Docetaxel—head and neck cancer	0.00178	0.00432	CcSEcCtD
Etravirine—Cardiac disorder—Docetaxel—head and neck cancer	0.00177	0.00429	CcSEcCtD
Etravirine—Angiopathy—Docetaxel—head and neck cancer	0.00173	0.0042	CcSEcCtD
Etravirine—Dizziness—Hydroxyurea—head and neck cancer	0.00172	0.00418	CcSEcCtD
Etravirine—Immune system disorder—Docetaxel—head and neck cancer	0.00172	0.00418	CcSEcCtD
Etravirine—Mediastinal disorder—Docetaxel—head and neck cancer	0.00172	0.00417	CcSEcCtD
Etravirine—Nausea—Vinblastine—head and neck cancer	0.0017	0.00412	CcSEcCtD
Etravirine—Insomnia—Fluorouracil—head and neck cancer	0.0017	0.00412	CcSEcCtD
Etravirine—Paraesthesia—Fluorouracil—head and neck cancer	0.00168	0.00409	CcSEcCtD
Etravirine—Mental disorder—Docetaxel—head and neck cancer	0.00167	0.00405	CcSEcCtD
Etravirine—Somnolence—Fluorouracil—head and neck cancer	0.00167	0.00405	CcSEcCtD
Etravirine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.00166	0.0221	CbGpPWpGaD
Etravirine—Malnutrition—Docetaxel—head and neck cancer	0.00166	0.00403	CcSEcCtD
Etravirine—Vomiting—Hydroxyurea—head and neck cancer	0.00166	0.00402	CcSEcCtD
Etravirine—Rash—Hydroxyurea—head and neck cancer	0.00164	0.00399	CcSEcCtD
Etravirine—Dermatitis—Hydroxyurea—head and neck cancer	0.00164	0.00398	CcSEcCtD
Etravirine—Headache—Hydroxyurea—head and neck cancer	0.00163	0.00396	CcSEcCtD
Etravirine—Decreased appetite—Fluorouracil—head and neck cancer	0.00163	0.00396	CcSEcCtD
Etravirine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00162	0.00393	CcSEcCtD
Etravirine—Pain—Fluorouracil—head and neck cancer	0.0016	0.00389	CcSEcCtD
Etravirine—Nausea—Hydroxyurea—head and neck cancer	0.00155	0.00376	CcSEcCtD
Etravirine—Feeling abnormal—Fluorouracil—head and neck cancer	0.00155	0.00375	CcSEcCtD
Etravirine—Anaemia—Docetaxel—head and neck cancer	0.00153	0.00372	CcSEcCtD
Etravirine—Syncope—Docetaxel—head and neck cancer	0.00149	0.00361	CcSEcCtD
Etravirine—Body temperature increased—Fluorouracil—head and neck cancer	0.00148	0.0036	CcSEcCtD
Etravirine—ABCB4—Fatty acid, triacylglycerol, and ketone body metabolism—CYP1A1—head and neck cancer	0.00148	0.0197	CbGpPWpGaD
Etravirine—Loss of consciousness—Docetaxel—head and neck cancer	0.00146	0.00354	CcSEcCtD
Etravirine—Convulsion—Docetaxel—head and neck cancer	0.00144	0.00349	CcSEcCtD
Etravirine—Hypertension—Docetaxel—head and neck cancer	0.00143	0.00348	CcSEcCtD
Etravirine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00141	0.0188	CbGpPWpGaD
Etravirine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.0014	0.0034	CcSEcCtD
Etravirine—Hypersensitivity—Fluorouracil—head and neck cancer	0.00138	0.00335	CcSEcCtD
Etravirine—Dry mouth—Docetaxel—head and neck cancer	0.00138	0.00335	CcSEcCtD
Etravirine—Confusional state—Docetaxel—head and neck cancer	0.00137	0.00331	CcSEcCtD
Etravirine—ABCB4—Metabolism—UROD—head and neck cancer	0.00135	0.018	CbGpPWpGaD
Etravirine—Infection—Docetaxel—head and neck cancer	0.00135	0.00326	CcSEcCtD
Etravirine—Shock—Docetaxel—head and neck cancer	0.00133	0.00323	CcSEcCtD
Etravirine—Nervous system disorder—Docetaxel—head and neck cancer	0.00133	0.00322	CcSEcCtD
Etravirine—Thrombocytopenia—Docetaxel—head and neck cancer	0.00133	0.00322	CcSEcCtD
Etravirine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00132	0.0176	CbGpPWpGaD
Etravirine—Skin disorder—Docetaxel—head and neck cancer	0.00132	0.00319	CcSEcCtD
Etravirine—Anorexia—Docetaxel—head and neck cancer	0.00129	0.00313	CcSEcCtD
Etravirine—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—head and neck cancer	0.00129	0.0172	CbGpPWpGaD
Etravirine—Diarrhoea—Fluorouracil—head and neck cancer	0.00128	0.00311	CcSEcCtD
Etravirine—Dizziness—Fluorouracil—head and neck cancer	0.00124	0.00301	CcSEcCtD
Etravirine—Insomnia—Docetaxel—head and neck cancer	0.00122	0.00297	CcSEcCtD
Etravirine—Paraesthesia—Docetaxel—head and neck cancer	0.00122	0.00295	CcSEcCtD
Etravirine—Somnolence—Docetaxel—head and neck cancer	0.0012	0.00292	CcSEcCtD
Etravirine—Vomiting—Fluorouracil—head and neck cancer	0.00119	0.00289	CcSEcCtD
Etravirine—Rash—Fluorouracil—head and neck cancer	0.00118	0.00287	CcSEcCtD
Etravirine—Dermatitis—Fluorouracil—head and neck cancer	0.00118	0.00287	CcSEcCtD
Etravirine—Decreased appetite—Docetaxel—head and neck cancer	0.00118	0.00286	CcSEcCtD
Etravirine—Headache—Fluorouracil—head and neck cancer	0.00118	0.00285	CcSEcCtD
Etravirine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00117	0.00284	CcSEcCtD
Etravirine—Fatigue—Docetaxel—head and neck cancer	0.00117	0.00283	CcSEcCtD
Etravirine—Pain—Docetaxel—head and neck cancer	0.00116	0.00281	CcSEcCtD
Etravirine—Constipation—Docetaxel—head and neck cancer	0.00116	0.00281	CcSEcCtD
Etravirine—CYP2C19—Xenobiotics—CYP1A1—head and neck cancer	0.00113	0.0151	CbGpPWpGaD
Etravirine—Feeling abnormal—Docetaxel—head and neck cancer	0.00112	0.00271	CcSEcCtD
Etravirine—Nausea—Fluorouracil—head and neck cancer	0.00111	0.0027	CcSEcCtD
Etravirine—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00111	0.00269	CcSEcCtD
Etravirine—CYP2C19—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.00109	0.0145	CbGpPWpGaD
Etravirine—Body temperature increased—Docetaxel—head and neck cancer	0.00107	0.0026	CcSEcCtD
Etravirine—Abdominal pain—Docetaxel—head and neck cancer	0.00107	0.0026	CcSEcCtD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.00105	0.014	CbGpPWpGaD
Etravirine—CYP2C9—Xenobiotics—CYP1A1—head and neck cancer	0.00103	0.0137	CbGpPWpGaD
Etravirine—Hypersensitivity—Docetaxel—head and neck cancer	0.000997	0.00242	CcSEcCtD
Etravirine—CYP2C9—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000991	0.0132	CbGpPWpGaD
Etravirine—Asthenia—Docetaxel—head and neck cancer	0.000971	0.00236	CcSEcCtD
Etravirine—Diarrhoea—Docetaxel—head and neck cancer	0.000926	0.00225	CcSEcCtD
Etravirine—Dizziness—Docetaxel—head and neck cancer	0.000895	0.00217	CcSEcCtD
Etravirine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000868	0.0116	CbGpPWpGaD
Etravirine—Vomiting—Docetaxel—head and neck cancer	0.000861	0.00209	CcSEcCtD
Etravirine—Rash—Docetaxel—head and neck cancer	0.000854	0.00207	CcSEcCtD
Etravirine—Dermatitis—Docetaxel—head and neck cancer	0.000853	0.00207	CcSEcCtD
Etravirine—Headache—Docetaxel—head and neck cancer	0.000848	0.00206	CcSEcCtD
Etravirine—CYP2C19—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.000839	0.0112	CbGpPWpGaD
Etravirine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.000812	0.0108	CbGpPWpGaD
Etravirine—Nausea—Docetaxel—head and neck cancer	0.000804	0.00195	CcSEcCtD
Etravirine—CYP3A4—Estrogen metabolism—GSTM1—head and neck cancer	0.00078	0.0104	CbGpPWpGaD
Etravirine—CYP3A4—Estrogen metabolism—CYP1A1—head and neck cancer	0.000739	0.00986	CbGpPWpGaD
Etravirine—CYP3A4—Xenobiotics—CYP1A1—head and neck cancer	0.000679	0.00907	CbGpPWpGaD
Etravirine—CYP3A4—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000653	0.00872	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000594	0.00793	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000588	0.00785	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—NAT2—head and neck cancer	0.00056	0.00747	CbGpPWpGaD
Etravirine—CYP2C19—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000548	0.00732	CbGpPWpGaD
Etravirine—CYP2C19—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000543	0.00724	CbGpPWpGaD
Etravirine—CYP2C9—Arachidonic acid metabolism—GPX1—head and neck cancer	0.0005	0.00667	CbGpPWpGaD
Etravirine—CYP2C9—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000495	0.0066	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—DPYD—head and neck cancer	0.000491	0.00655	CbGpPWpGaD
Etravirine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000469	0.00626	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—YAP1—head and neck cancer	0.000466	0.00621	CbGpPWpGaD
Etravirine—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000463	0.00618	CbGpPWpGaD
Etravirine—CYP2C19—Biological oxidations—NAT2—head and neck cancer	0.000431	0.00576	CbGpPWpGaD
Etravirine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000428	0.00571	CbGpPWpGaD
Etravirine—CYP2C19—Metapathway biotransformation—NAT2—head and neck cancer	0.000426	0.00568	CbGpPWpGaD
Etravirine—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000422	0.00563	CbGpPWpGaD
Etravirine—CYP2C9—Biological oxidations—NAT2—head and neck cancer	0.000393	0.00525	CbGpPWpGaD
Etravirine—CYP2C9—Metapathway biotransformation—NAT2—head and neck cancer	0.000388	0.00518	CbGpPWpGaD
Etravirine—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.00038	0.00507	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	0.000354	0.00473	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.00035	0.00467	CbGpPWpGaD
Etravirine—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000349	0.00466	CbGpPWpGaD
Etravirine—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000347	0.00463	CbGpPWpGaD
Etravirine—CYP2C19—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000323	0.00431	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	0.000322	0.0043	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	0.000305	0.00407	CbGpPWpGaD
Etravirine—CYP2C9—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000294	0.00393	CbGpPWpGaD
Etravirine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000282	0.00376	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—TYMS—head and neck cancer	0.00028	0.00373	CbGpPWpGaD
Etravirine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000278	0.00372	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—GSTM1—head and neck cancer	0.000276	0.00369	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—CASP8—head and neck cancer	0.000268	0.00358	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—GPX1—head and neck cancer	0.000265	0.00353	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—CYP1A1—head and neck cancer	0.000262	0.0035	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—NAT2—head and neck cancer	0.000259	0.00346	CbGpPWpGaD
Etravirine—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	0.000256	0.00341	CbGpPWpGaD
Etravirine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000229	0.00305	CbGpPWpGaD
Etravirine—ABCB4—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	0.000215	0.00287	CbGpPWpGaD
Etravirine—CYP2C19—Biological oxidations—GSTM1—head and neck cancer	0.000213	0.00284	CbGpPWpGaD
Etravirine—CYP2C19—Metapathway biotransformation—GSTM1—head and neck cancer	0.00021	0.0028	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—IL2—head and neck cancer	0.000203	0.0027	CbGpPWpGaD
Etravirine—CYP2C19—Biological oxidations—CYP1A1—head and neck cancer	0.000202	0.0027	CbGpPWpGaD
Etravirine—CYP2C19—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000199	0.00266	CbGpPWpGaD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	0.000199	0.00265	CbGpPWpGaD
Etravirine—ABCB1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000195	0.0026	CbGpPWpGaD
Etravirine—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	0.000194	0.00259	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.000193	0.00258	CbGpPWpGaD
Etravirine—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	0.000192	0.00256	CbGpPWpGaD
Etravirine—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	0.000184	0.00246	CbGpPWpGaD
Etravirine—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000182	0.00242	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—UROD—head and neck cancer	0.000178	0.00237	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—UROD—head and neck cancer	0.000173	0.00231	CbGpPWpGaD
Etravirine—ABCB1—Allograft Rejection—VEGFA—head and neck cancer	0.000172	0.0023	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—UROD—head and neck cancer	0.000162	0.00216	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—PTGS2—head and neck cancer	0.000156	0.00208	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000138	0.00184	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—PTEN—head and neck cancer	0.000136	0.00181	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	0.000132	0.00177	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	0.000128	0.00171	CbGpPWpGaD
Etravirine—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	0.000127	0.00169	CbGpPWpGaD
Etravirine—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	0.000126	0.00169	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.000126	0.00168	CbGpPWpGaD
Etravirine—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	0.000121	0.00162	CbGpPWpGaD
Etravirine—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	0.00012	0.0016	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	0.000114	0.00151	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	0.000108	0.00144	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—UROD—head and neck cancer	0.000107	0.00143	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	9.74e-05	0.0013	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—PIK3CA—head and neck cancer	9.59e-05	0.00128	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	9.4e-05	0.00125	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	8.49e-05	0.00113	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	8.03e-05	0.00107	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	7.84e-05	0.00105	CbGpPWpGaD
Etravirine—ABCB4—Metabolism—AKT1—head and neck cancer	7.83e-05	0.00105	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	7.76e-05	0.00104	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	7.65e-05	0.00102	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	7.64e-05	0.00102	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—NAT2—head and neck cancer	7.38e-05	0.000985	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—NAT2—head and neck cancer	7.2e-05	0.000961	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	7.15e-05	0.000954	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	7.07e-05	0.000944	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—NAT2—head and neck cancer	6.73e-05	0.000898	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	6.63e-05	0.000885	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—DPYD—head and neck cancer	6.47e-05	0.000863	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	6.42e-05	0.000856	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—DPYD—head and neck cancer	6.32e-05	0.000843	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—YAP1—head and neck cancer	6.14e-05	0.000819	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—YAP1—head and neck cancer	5.99e-05	0.0008	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—DPYD—head and neck cancer	5.9e-05	0.000787	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—YAP1—head and neck cancer	5.6e-05	0.000747	CbGpPWpGaD
Etravirine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	5.42e-05	0.000723	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	4.61e-05	0.000616	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—NAT2—head and neck cancer	4.44e-05	0.000592	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	4.21e-05	0.000561	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	4.02e-05	0.000537	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—DPYD—head and neck cancer	3.89e-05	0.000519	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—YAP1—head and neck cancer	3.69e-05	0.000493	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—TYMS—head and neck cancer	3.69e-05	0.000492	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	3.67e-05	0.00049	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—GSTM1—head and neck cancer	3.64e-05	0.000486	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—TYMS—head and neck cancer	3.6e-05	0.00048	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—GSTM1—head and neck cancer	3.56e-05	0.000475	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—GPX1—head and neck cancer	3.49e-05	0.000466	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—CYP1A1—head and neck cancer	3.45e-05	0.000461	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—GPX1—head and neck cancer	3.41e-05	0.000455	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—CYP1A1—head and neck cancer	3.37e-05	0.00045	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—TYMS—head and neck cancer	3.36e-05	0.000449	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—GSTM1—head and neck cancer	3.32e-05	0.000443	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—GPX1—head and neck cancer	3.18e-05	0.000425	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—CYP1A1—head and neck cancer	3.15e-05	0.00042	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.84e-05	0.000379	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	2.59e-05	0.000345	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—TYMS—head and neck cancer	2.22e-05	0.000296	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—GSTM1—head and neck cancer	2.19e-05	0.000292	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—GPX1—head and neck cancer	2.1e-05	0.00028	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—CYP1A1—head and neck cancer	2.08e-05	0.000277	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PTGS2—head and neck cancer	2.05e-05	0.000274	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PTGS2—head and neck cancer	2.01e-05	0.000268	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PTGS2—head and neck cancer	1.87e-05	0.00025	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PTEN—head and neck cancer	1.79e-05	0.000239	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PTEN—head and neck cancer	1.75e-05	0.000233	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PTEN—head and neck cancer	1.63e-05	0.000218	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—PIK3CA—head and neck cancer	1.26e-05	0.000169	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PTGS2—head and neck cancer	1.24e-05	0.000165	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—PIK3CA—head and neck cancer	1.23e-05	0.000165	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—PIK3CA—head and neck cancer	1.15e-05	0.000154	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PTEN—head and neck cancer	1.08e-05	0.000144	CbGpPWpGaD
Etravirine—CYP2C19—Metabolism—AKT1—head and neck cancer	1.03e-05	0.000138	CbGpPWpGaD
Etravirine—ABCB1—Metabolism—AKT1—head and neck cancer	1.01e-05	0.000134	CbGpPWpGaD
Etravirine—CYP2C9—Metabolism—AKT1—head and neck cancer	9.42e-06	0.000126	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—PIK3CA—head and neck cancer	7.6e-06	0.000101	CbGpPWpGaD
Etravirine—CYP3A4—Metabolism—AKT1—head and neck cancer	6.21e-06	8.29e-05	CbGpPWpGaD
